Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, confirmed that its Board of Directors is evaluating strategic alternatives to enhance shareholder value, including by pursuing a process with potential bidders to explore a possible merger or sale of the Company. The Company has engaged Goldman Sachs as its financial advisor and Cravath, Swaine & Moore LLP as its legal advisor to assist the Board in its evaluation.
Millipore has not set a definitive timetable for completion of its evaluation and there can be no assurances that the process will result in any transaction. The Company does not intend to disclose developments regarding this process unless and until the Board of Directors has approved a specific transaction.
Date: February 24, 2010
Source: Millipore Corporation
Filed Under: Drug Discovery
